Phase II Pharmacokinetic and Pharmacodynamic Study of DEX in Subjects Aged 12 Months Through <24 Months
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the pharmacokinetic, pharmacodynamic, and safety
of dexmedetomidine at 2 different dose levels in pediatric subjects, aged 12 months through
<24 months, administered as an intravenous loading dose followed by continuous infusion for a
minimum of 6 hours and up to 24 hours in an intensive care setting.
Phase:
Phase 2
Details
Lead Sponsor:
Hospira, Inc. Hospira, now a wholly owned subsidiary of Pfizer